212 related articles for article (PubMed ID: 25109354)
1. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
2. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.
Peng B; Lei N; Chai Y; Chan EK; Zhang JY
Mol Biosyst; 2015 Jan; 11(1):105-14. PubMed ID: 25325377
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
4. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Wei L; Qu W; Sun J; Wang X; Lv L; Xie L; Song X
Cancer Gene Ther; 2014 May; 21(5):194-9. PubMed ID: 24874844
[TBL] [Abstract][Full Text] [Related]
6. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer.
Ma L; Wen ZS; Liu Z; Hu Z; Ma J; Chen XQ; Liu YQ; Pu JX; Xiao WL; Sun HD; Zhou GB
PLoS One; 2011; 6(5):e20159. PubMed ID: 21655278
[TBL] [Abstract][Full Text] [Related]
7. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
8. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.
Puustinen P; Rytter A; Mortensen M; Kohonen P; Moreira JM; Jäättelä M
J Cell Biol; 2014 Mar; 204(5):713-27. PubMed ID: 24590173
[TBL] [Abstract][Full Text] [Related]
9. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
10. CIP2A regulates proliferation and apoptosis of multiple myeloma cells.
Zheng Z; Qiao Z; Chen W; Gong R; Wang Y; Xu L; Ma Y; Zhang L; Lu Y; Jiang B; Li G; Dong C
Mol Med Rep; 2016 Sep; 14(3):2705-9. PubMed ID: 27484817
[TBL] [Abstract][Full Text] [Related]
11. (+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis.
Monga J; Suthar SK; Rohila D; Joseph A; Chauhan CS; Sharma M
Phytomedicine; 2022 Jul; 101():154116. PubMed ID: 35525235
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma.
Gao H; Li Y; Lin T; Cheng Y; Ma Y
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):196-202. PubMed ID: 31431792
[TBL] [Abstract][Full Text] [Related]
13. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
14. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Zhang Y; Huang P; Liu X; Xiang Y; Zhang T; Wu Y; Xu J; Sun Z; Zhen W; Zhang L; Si Y; Liu Y
J Pharmacol Sci; 2018 Jul; 137(3):305-312. PubMed ID: 30119963
[TBL] [Abstract][Full Text] [Related]
15. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
16. CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer.
Peng B; Chai Y; Li Y; Liu X; Zhang J
BMC Cancer; 2015 Nov; 15():895. PubMed ID: 26560124
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
18. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
[TBL] [Abstract][Full Text] [Related]
19. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
20. CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.
Zhai M; Cong L; Han Y; Tu G
Tumour Biol; 2014 Feb; 35(2):1123-8. PubMed ID: 24014087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]